Why is Medicamen Biotec falling/rising?

As of 01-Sep, Medicamen Biotech Ltd is currently priced at 345.05, reflecting an increase of 1.35 (0.39%). The stock opened with a gain of 2.81% today and reached an intraday high of Rs 354.45, indicating some positive momentum. However, it remains close to its 52-week low, just 0.88% away, and has underperformed significantly over the past month with a decline of 10.27%. Despite a recent outperformance against its sector by 0.42%, the stock is trading below all major moving averages, and there has been a notable decrease in investor participation, with delivery volume dropping by 84.27% compared to the 5-day average. The company has a low debt-to-equity ratio and has seen profits rise by 28.3% over the past year, but the stock's long-term growth prospects are hindered by a declining operating profit trend.
Broader market context indicates that while Medicamen Biotech has experienced a slight uptick today, it has consistently underperformed against the benchmark, with a year-to-date return of -32.24% compared to a positive 2.85% for the Sensex. The stock's performance over the last three years has been particularly poor, with a staggering decline of 71.26% against a 36.75% gain in the benchmark. This consistent underperformance, coupled with flat results in recent financial reports and low cash reserves, suggests that investor sentiment remains cautious, impacting the stock's ability to recover despite today's modest rise.